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may especially benefit from the increased selenium intake. 
Surprisingly, considering gene and time interaction, GPX1 
polymorphism was observed to modify the level of DNA 
strand breaks during washout, showing a significant 
increase in GPX1 wild-type homozygotes. Regardless of 
the genotype, selenium supplementation was associated 
with a selectively suppressed selenoprotein mRNA expres-
sion and inconsistent changes in oxidative stress response, 
indicating for overlapped, antioxidant, and prooxidant 
effects. Intriguingly, DNA damage was not influenced by 
supplementation, but it was significantly increased during 
washout.
Conclusions These results point to an unclear relationship 
between selenium, genotype, and DNA damage.
Keywords Selenium · Selenoproteins · Oxidative 
stress · DNA damage · Gene expression · Selenium 
supplementation
Background
Selenium (Se) is an essential trace element, the importance 
of which for human health is indicated by the presence of 
at least 25 selenoproteins containing the element in a form 
of selenocysteine (Sec), the twenty-first proteinogenic 
amino acid. The unusual uniqueness of selenium stems 
from the fact that Sec is incorporated into selenoprotein 
polypeptide chain cotranslationally, driven by UGA mRNA 
codon in the presence of a specific molecular machinery, 
including Sec-tRNA, Sec insertion sequence (SECIS) ele-
ment, and protein factors such as SECIS-binding protein 
(SBP2) and Sec-specific translation elongation factor (eEF-
Sec), which all together allow for insertion of Sec instead 
of premature termination of biosynthesis (as UGA usually 
Abstract 
Purpose Selenium, both essential and toxic element, is 
considered to protect against cancer, though human sup-
plementation trials have generated many inconsistent data. 
Genetic background may partially explain a great variabil-
ity of the studies related to selenium and human health. 
The aim of this study was to assess whether functional 
polymorphisms within two selenoprotein-encoding genes 
modify the response to selenium at the level of oxidative 
stress, DNA damage, and mRNA expression, especially in 
the individuals with a relatively low selenium status.
Methods The trial involved 95 non-smoking individu-
als, stratified according to GPX1 rs1050450 and SEPP1 
rs3877899 genotypes, and supplemented with selenium 
yeast (200 µg) for 6 weeks. Blood was collected at four 
time points, including 4 weeks of washout.
Results After genotype stratification, the effect of GPX1 
rs1050450 on lower GPx1 activity responsiveness was 
confirmed; however, in terms of DNA damage, we failed 
to indicate that individuals homozygous for variant allele 
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serves as the termination codon) [1, 2]. The uniqueness of 
selenium is also reflected by its biological activity, in terms 
of which the element is most often described as “double-
edge sword,” “essential poison,” or “two-faced element” 
[3]. That is due to high redox properties—Se exerts both 
nutritional and toxic activities within a relatively nar-
row range of doses, highlighted by a relatively small dif-
ference between the recommended daily intake (55 µg or 
70 µg in USA and Europe, respectively) and the estimated 
upper tolerable limit (300, 400, or 450 µg/day according 
to different sources) [4–6]. Most of the scientific interest 
related to Se is associated with its anticancer properties, 
which have been suggested based on numerous in vitro 
and in vivo studies as well as on some, although not all, 
human observational studies and human long-term sup-
plementation trials [7, 8]. Mechanism of anticancer activ-
ity of Se remains elusive, but it is generally considered that 
it results both from antioxidant- and redox-related proper-
ties of Se, exerted at a nutritional level and linked mainly 
to the activity of selenium-dependent enzymes (selenopro-
teins with catalytic activity), as well as from its prooxidant 
effects, observed at supranutritional intake and associated 
with the activity of low molecular weight Se compounds 
[9–12]. However, in the recent years, the hypothesis on 
cancer protective activity of Se has been seriously under-
mined by the results of a large, randomized double-blind 
prospective study, i.e., SELECT, which has been conducted 
to test whether Se (as selenomethionine) and vitamin E (as 
alpha-tocopherol) may reduce the risk of prostate cancer in 
men, and which has finally failed to indicate any protective 
effects of the element, either alone or in the combination 
with vitamin E [13]. Additionally, some concern has been 
paid to Se supplementation in terms of its possible diabe-
togenic effects, adding more uncertainty to assessing the 
relationship between selenium and human health [14, 15].
On the basis of several gene association studies, pointing 
to the importance of genetic polymorphism in the risk of 
human cancer as well as other diseases, it has been hypoth-
esized that biological activity of Se in the human body may 
be modified by genetic polymorphism of selected seleno-
proteins [16, 17]. Human selenoproteins cover many bio-
logically important functions like those related to antioxi-
dant defense system, thyroid hormone metabolism, and 
redox balance maintenance, all of which are driven mainly 
by redox-related selenoproteins, including five glutathione 
peroxidases (GPx1, GPx2, GPx3, GPx4, GPx6), three iodo-
thyronine deiodinases (DI1, DI2, DI3), three thioredoxin 
reductases (TRxR1, TRxR2, TRxR3), or methionine-R-
sulfoxide reductase (MsrB1, known also as SelR or SelX). 
Selenoprotein P (Sepp1) is the only selenoprotein which 
possesses multiple Sec residues and which is mainly 
responsible for Se transport within the body, but has been 
also shown to exert catalytic and antioxidant activities [18]. 
Functions of other selenoproteins are specifically linked 
to the selenoprotein synthesis (selenophoshate synthetase 
2—SPS2), muscle development (selenoprotein N—SelN) 
or endoplasmic reticulum function (15-kDa selenopro-
tein—Sep15, selenoprotein S—SelS, selenoprotein K—
SelK), whereas functions of many other (like selenoprotein 
H—SelH, selenoprotein I—SelI, selenoprotein M—SelM, 
selenoprotein O—SelO, selenoprotein W—SelW, seleno-
protein T—SelT, or selenoprotein V—SelV) still remain 
unknown [19, 20]. It has been demonstrated that some pol-
ymorphic variants in genes encoding for selected seleno-
proteins, including GPX1 (glutathione peroxidase 1), GPX4 
(glutathione peroxidase 4), SEPP1 (selenoprotein P), SELS 
(selenoprotein S), and SEP15 (15-kDa selenoprotein), have 
functional significance and may influence expression or 
activity of the protein either at the transcription, translation, 
or posttranslational level, thus explaining their association 
with the altered risk of cancer at several sites [17].
Despite the commonly appreciated approach to include 
genetic profile in the design of intervention trials or in the 
interpretation of study results, only few authors have fol-
lowed this direction, and those who have, focused only 
on single, specific end points linked mainly to oxidative 
stress markers and/or DNA damage [21–25]. Notably, the 
genotype modifying effects are more likely to be observed 
within the subjects with a relatively low Se status [24]. 
Thus, the aim of this study was to analyze the potential 
influence of two functional single-nucleotide polymor-
phisms (SNPs), present within the coding region of two 
selenoprotein genes: GPX1 rs1050450 (Pro198Leu) and 
SEPP1 rs3877899 (Ala234Thr), on the multilevel biologi-
cal response to Se supplementation. Due to a low dietary 
intake of Se in the Polish population [26], individuals from 
Poland who constituted the study group seemed to be rel-
evant to investigate the possible gene–selenium interac-
tions. Biomarkers of relevance included markers of Se 
status (plasma Se and Sepp1 concentrations), markers of 
oxidative stress (activity of antioxidant enzymes in plasma 
or erythrocytes, plasma lipid peroxidation, oxidative burst 
in the whole-blood leukocytes), DNA strand breaks, DNA 
oxidation, and mRNA expression of selected encoding 
selenoproteins or related genes (GPX1, GPX4, TRXR1, 
SEP15, SEPP1, SELS, SELW, SBP2).
Methods
Study design
By means of advertisement in different public places, 517 
residents of Lodz in the age 18–60 were recruited for the 
study. Questionnaire data and 4 mL of fasting blood were 
collected from the subjects, followed by DNA isolation and 
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prospective genotyping for GPX1 rs1050450 and SEPP1 
rs3877899. In a whole group of 517 recruited subjects, 
GPX1 allelic variants were in Hardy–Weinberg equilibrium 
(p = 0.582), and the genotype distribution was as follows: 
46, 43, and 11 % for ProPro, ProLeu, and LeuLeu, respec-
tively. SEPP1 genotype frequencies were 60, 32, and 7.5 % 
for AlaAla, AlaThr, and ThrThr, respectively, with a slight 
deviation from Hardy–Weinberg equilibrium (p = 0.013). 
The exclusion criteria for the supplementation trial included 
current smoking, chronic diseases such as cancer, diabetes, 
or cardiovascular disease, BMI higher than 35 as well as 
incomplete data for genetic analyses. Altogether 137 sub-
jects were excluded. Further selection of the remaining 380 
volunteers was based on the approximate major and minor 
allele distribution in order to obtain an as high as possible 
number of individuals with rare genotypes (GPX1 Leu/Leu 
and SEPP1 Thr/Thr) and to increase statistical power of 
comparison tests. Namely, all the subjects with rare geno-
types were asked to participate in the supplementation trial, 
whereas subjects with common alleles were matched for 
age and BMI. Altogether 95 subjects agreed to participate 
in the trial. The study group characteristics are presented in 
Table 1. Genotype distribution is shown in Table 2, whereas 
Figure S1 presents the numbers of subjects with different 
genotype combinations. The selected 95 subjects, including 
43 men and 52 women at the mean age of 35.6 years, were 
receiving 200 µg of selenium in a form of selenium yeast for 
6 weeks. Se yeast tablets were obtained commercially, and 
all were from the same batch. During the supplementation 
trial, as well as during the washout period, the participants 
were asked not to take any supplements containing vitamins 
and selenium or other elements. Fasting blood was collected 
during the study at four time points: before the supplemen-
tation assigned as baseline (the first day of the trial, before 
taking the first tablet), after 2 and 6 weeks of supplementa-
tion, and after 4 weeks of the washout period. Blood samples 
were collected from each participant in two heparin tubes 
Table 1  Baseline characteristics of the study group




Age (years) 95 (100) 35.6 ± 10.8 (18-60)
 <30 31 (32.6)
 31–40 41 (43.2)
 41–50 9 (9.5)
 51–60 14 (14.7)
BMI (kg/m2) 95 (100) 23.8 ± 3.1 (17.9-34.9)
 <25 68 (71.6)
 25–30 23 (24.2)
 >30 4 (4.2)
Smoking
 Current 0 (0)
 Ever 25 (26.3)
 In the past 5 years 10 (9.5)
 Never 70 (73.7)
Passive smoking
 Yes 25 (26.3)
 No 70 (73.7)
Alcohol consumption
 Never 5 (5.3)
 Less than 1 day per month 30 (31.6)
 Less than 1 day per week 34 (35.8)
 Up to 2 days per week 25 (26.3)
 3–5 days per week or more 1 (1.1)
Vitamin or mineral supplements use
 Yes, sporadically 34 (35.8)
 Yes, regularly 23 (24.2)
 No 38 (40.0)
Selenium containing supplements use in the past 6 months
 Yes 5 (5.3)
 No 90 (94.7)
Table 2  Genotype distribution for GPX1 rs1050450 and SEPP1 rs3877899 polymorphisms and baseline characteristics according to genotype
* Skewed data; for these parameters, p values (one-way ANOVA) were calculated for log-transformed data
a p for linear trend = 0.04
Genotype N (%) Age, years (median 
and range)
Sex (females/males) BMI (median and 
range)
Plasma Se, µg/L 
(median and range)
Plasma Sepp1 ng/mL 
(median and range) *
GPX1 rs1050450
Pro/Pro 39 (41 %) 33.0 (18.0–60.0) 1.29 (22/17) 22.9 (18.0–33.1) 63.3 (34.3–109.1) 3.9 (0.9–26.4)
Pro/Leu 35 (37 %) 37.0 (18.0–58.0) 1.06 (18/17) 23.7 (17.9–31.1) 62.7 (35.8–103.2) 4.2 (1.3–36.0)
Leu/Leu 21 (22 %) 34.0 (18.0–58.0) 1.33 (12/9) 24.6 (20.1–34.9) 62.5 (37.2–96.2) 3.6 (1.0–6.4)
SEPP1 rs3877899
Ala/Ala 46 (48 %) 33.0 (20.0–58.0) 0.92 (22/24) 23.4 (18.7–31.1) 66.3 (37.2–106.1)a 3.1 (1.0–26.9)
Ala/Thr 29 (31 %) 33.0 (18.0–58.0) 1.90 (19/10) 22.9 (17.9–27.7) 68.9 (34.3–96.2)a 4.2 (0.9–36.0)
Thr/Thr 20 (21 %) 36.5 (18.0–60.0) 1.22 (11/9) 23.7 (18.9–34.9) 52.0 (35.8–109.1)a 4.3 (1.1–23.4)
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and two EDTA tubes. The material collected in the first hep-
arinized tube (7.5 mL) was fractioned by centrifugation into 
plasma, buffy coat, and erythrocytes and frozen at −20 °C 
until biochemical analyses. Whole blood (4.5 mL) from the 
second heparin tube was used for oxidative burst assessment, 
which was performed at the day of blood collection (this 
analysis was performed only at two time points: at baseline 
and after 2 weeks of supplementation). EDTA whole blood 
(1.5 mL) was used for leukocyte lysate preparation, which 
was subsequently stored at −70 °C until mRNA isolation 
(for gene expression analysis). Whole blood (2.7 mL) from 
the second EDTA tube was used to prepare agarose slides 
for the comet assay (this analysis was performed at three 
time points: at baseline, after 6 weeks of supplementation, 
and after 4 weeks of the washout period). Along with the 
blood collection, detailed questionnaire data were collected 
each time, concerning current health status (well-being with 
respect to adverse health effects), intake of medications, die-
tary supplements, herbs or pharmacological treatment with 
hormones, antibiotics, statins, and other. All the analyses, 
apart from the oxidative burst assessment, were conducted 
after completing the study, and all the samples were blinded 
in terms of genotype and the time point of their collection. 
All the study participants gave written informed consent, and 
the subjects who were enrolled for the supplementation trial 
received detailed, written, and oral information about the 
trial. The study was approved by the Local Ethics Committee 
(Ethical Institutional Review Board at the Nofer Institute of 
Occupational Medicine, Lodz, Poland).
DNA isolation and SNP genotyping
DNA was isolated from buffy coat, using QIAamp DNA 
Blood Mini Kit (Qiagen, Hilden, Germany). Allelic dis-
crimination for the two studied polymorphisms was per-
formed using the real-time PCR method and CFX96™ 
Real-Time PCR Detection System (Bio-Rad, Hercules, 
CA, USA). GPX1 rs1050450 genotyping was conducted 
using the high-resolution melt curve (HRM) technique. 
Oligonucleotide sequences for PCR primers, designed by 
Beacon Designer™ (PREMIER Biosoft, Palo Alto, CA, 
USA), were as follows: 5′-GCCGCTTCCAGACCATTG-3′ 
(forward) and 5′-GGTGTTCCTCCCTCGTAG-3′ (reverse). 
Data analysis was performed using Bio-Rad CFX Man-
ager and Bio-Rad Precision Melt Analysis Software. Iden-
tification of particular genotypes recognized by HRM was 
based on the comparison with the method introducing spe-
cific fluorescent probes, as described previously [27]. For 
SEPP1 rs3877899 analysis, the TaqMan® SNP Genotyping 
Assay (C_8709053_10, Life Technologies, Life Technolo-
gies, Carlsbad, CA, USA) was used. The call rate for two 
SNPs was >99 %, and the concordance of the blinded QC 
(n = 12) was 100 %.
mRNA isolation, cDNA synthesis, and gene expression
WBC lysates and mRNA isolation were performed using 
the QIAamp RNA Blood Mini Kit (Qiagen, Hilden, Ger-
many), and reverse transcription was performed using the 
QuantiTect Kit (Qiagen, Hilden, Germany). Both cDNA 
synthesis and real-time PCR were conducted in the Light 
Cycler 96 Real-Time PCR System (Roche, Indianapolis, 
IN, USA). cDNA was stored at −20 °C until gene expres-
sion experiments. Primers’ sequences and amplicons’ sizes 
are presented in Table S1. Real-time PCRs were carried out 
in three replications for each sample. 20 µL reaction mix-
ture contained 1 μL of cDNA, 10 μL of 2x FastStart SYBR 
Green Master (Roche, Indianapolis, IN, USA), 20 pmol of 
each primer, and nuclease-free water (Qiagen, Hilden, Ger-
many). PCR conditions were as follows: polymerase activa-
tion at 95 °C for 10 s, followed by 45 cycles: denaturation 
at 95 °C for 15 s, annealing at 60 °C for 45 s, and polym-
erization at 72 °C for 45 s. Inter- and intra-assay variations, 
as determined by three occasional, intra-experimental runs 
of five cDNA triplicates, were below 12 and 10 %, respec-
tively. PCR efficiencies were calculated using five dilutions 
of pooled cDNA, consisting of randomly selected samples. 
As confirmed by the initial data analysis, expression of the 
reference gene (GAPDH) was stable under experimental 
conditions. Normalized relative quantification of the target 
genes’ expression was evaluated including reaction effi-
ciency correction, by the use of the qbasePLUS software, 
version: 2.3) (Biogazelle NV, Zwijnaarde, Belgium).
Plasma selenium concentration
Plasma sample used for determination of selenium con-
centration was initially diluted with Triton X-100 (0.2 %, 
Sigma-Aldrich, St. Louis, MO, USA) in a proportion 1:1. 
Concentration was assessed using Zeeman flameless atomic 
absorption spectrometry (instrument Z-5000, Hitachi) with 
graphite tube and palladium/magnesium matrix modifier 
(Pd—1500 ppm, Mg—900 ppm). The limit of detection 
was 1.4 µg/L. The certified reference material Seronorm 
Trace Elements Serum (SERO AS, Billingstad, Norway) 
was used for the quality control assessment. The accuracy 
of the method and coefficient of variance (CV) were 1.3 
and 4.7 %, respectively.
Plasma selenoprotein P concentration
Sepp1 concentration was determined in plasma using the 
immunochemical Sandwich ELISA test (USCN Life Sci-
ence Inc kit, Hu, China). In brief, plasma samples were 
diluted 500–1000 times and added to the plate wells with 
biotin-conjugated polyclonal antibody specific for Sepp1. 
Next, avidin-conjugated horseradish peroxidase was added, 
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and after incubation with TMB (3,3′,5,5′-tetramethylben-
zidine), the substrate solution color change was observed 
proportionally to Sepp1 concentration. The reaction was 
terminated with sulfuric acid solution, and color intensity 
was measured at a wavelength of 450 nm. For each test, a 
standard curve was determined (range 0.78–50 ng/mL), and 
Sepp1 concentration was calculated after plotting logarith-
mic curve. Intra-assay and inter-assay variations were 8.0 
and 12.7 %, respectively.
Activity of antioxidant enzymes
Spectrophotometric methods were used to analyze blood 
compartments for the activity of GPx1, GPx3, SOD1, and 
Cp. The activity of glutathione peroxidases was deter-
mined in erythrocytes (GPx1) and plasma (GPx3) using the 
method of Paglia and Valentine [28] with t-butyl hydroper-
oxide as a substrate and following the rate of NADPH oxi-
dation by the coupled reaction with glutathione reductase. 
The rate of decrease in the absorbance, being proportional 
to the GPx activity, was read at a wavelength of 340 nm. 
The activity of SOD1 was determined in erythrocytes by 
the use of the method of Beauchamp and Fridovich [29], 
which relies on the inhibition by SOD1 of the reduction of 
nitro blue tetrazolium (NBT) by xanthine and xanthine oxi-
dase. The concentration of the reduced form of NBT was 
measured at a wavelength of 540 nm. The oxidase activity 
of Cp was determined in plasma according to the method 
described by Sunderman and Nomoto [30], with a PPD 
(p-phenylenediamine) as a substrate. The absorbance of 
the oxidation product was read at a wavelength of 535 nm. 
The activity of Cp was expressed as the amount of product 
formed per minute per 1 L of plasma. All the absorbance 
values were read using the Unicam UV4 UV/Vis spectro-
photometer (Cambridge, UK).
Total antioxidant capacity
The total antioxidant capacity of plasma was determined 
calorimetrically by the use of the Antioxidant Assay Kit 
(Cayman Chemical Company, Ann Arbor, MI, USA). 
Absorbance measurement was taken on a spectrophotom-
eter MultiScan GO (Thermo Scientific, Waltham, MA, 
USA).
Lipid peroxidation
Plasma concentration of thiobarbituric acid-reactive sub-
stances (TBARS) was determined using the spectrofluoro-
metric method, optimized by Wasowicz et al. [31]. TBA-
reactive compounds were extracted to butanol. The value 
of fluorescence of butanol layer was read at an excitation 
wavelength of 525 nm and an emission wavelength of 
547 nm, using the PerkinElmer Luminescence Spectrom-
eter LS50B (Norwalk, Ct, USA).
Oxidative burst
Oxidative burst (generation of reactive oxygen species, 
ROS) was measured using flow cytometry and fluorescent 
labeling with 2′,7′-dichlorodihydrofluorescein diacetate 
(DCFH2-DA, Sigma-Aldrich, St. Louis, MO, USA). The 
fluorescence was read in the FACSCanto II flow cytometer 
(BD Biosciences, San Jose, CA, USA) and expressed as 
the mean fluorescent intensity (MFI). The final results were 
expressed as the MFI ratio, calculated as the ratio of PMA 
stimulated cells MFI to MFI of basal ROS production. In 
each sample, at least 20,000 cells were examined.
DNA damage
DNA damage, including the strand breaks (SB) and alkali-
labile sites (ALS), was assayed in whole blood using alka-
line single-cell gel electrophoresis (SCGE; comet assay) 
method as described by Singh et al. [32] and modified by 
Mc Kelvey–Martin et al. [33]. One aliquot of whole blood 
was mixed with nine aliquots of RPMI-1640 medium and 
10 aliquots of 2 % (in PBS) molten agarose type VII (low 
gelling temperature). The mixture was then spread on a 
slide earlier covered with agarose type I (low EEO) at 1 % 
concentration in water and dried. The cells embedded in the 
agarose gel were lysed in cold lysing solution (2.5 M NaCl, 
100 mM Na2EDTA, 10 mM Tris base, pH 10, with 1 % 
Triton X-100 added just before use) at 4 °C for 1 h. Sub-
sequently, DNA was unwound in an alkaline electrophore-
sis buffer (1 mM Na2EDTA, 300 mM NaOH, pH 13) for 
20 min and electrophoresed in the same alkaline conditions 
(30 min, 25 V, 300 mA, 1.04 V/cm). The gels were then 
neutralized by rinsing three times with 0.4 M Tris buffer 
(pH 7.5), and the slides were dried for storage. In paral-
lel analyses, oxidatively generated damage to DNA bases 
was additionally identified as formamidopyrimidine glyco-
sylase (FPG)-sensitive sites using modified comet assay as 
described earlier by Collins et al. [34]. FPG enzyme was 
purchased from New England Biolabs (Hithchin, UK). 
After lysis, the slides were washed three times with an 
enzyme buffer (0.1 M KCl, 0.5 mM Na2EDTA, 40 mM 
HEPES–KOH, 0.2 mg/ml bovine serum albumin, pH 8) 
and incubated with FPG at 2.7 U/mL in this buffer (kept 
at −80 °C) for 30 min at 37 °C. The slides were then elec-
trophoresed and neutralized as described above. Finally, the 
slides were stained with 5 μg/mL DAPI, and 50 cells from 
each slide were analyzed using an Olympus fluorescence 
microscope (a BX40 instrument; Olympus, Tokyo, Japan) 
equipped with an image analysis system (Comet IV, Per-
ceptive Instruments, UK). For each participant, four slides 
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were prepared simultaneously: two for assessment of DNA 
strand breakage and the other two, which included also the 
FPG treatment, for the assessment of total DNA damage 
(i.e., DNA strand breakage and oxidatively generated DNA 
damage). Respective DNA damage was inferred based on 
the relative amount of DNA in the comet tail (henceforth 
referred to as % tail DNA) obtained via computer-aided 
image analysis. DNA oxidation damage was expressed as 
the difference between the total DNA damage and DNA 
strand breaks, i.e., “net FPG-sensitive sites.”
Statistical analysis
Data normality was assessed using Shapiro–Wilk test. In 
the case of abnormal distributions, an analysis was per-
formed on the log-transformed values. Baseline differ-
ences between males and females were assessed by the 
use of the t test, while correlations among baseline param-
eters and individuals’ characteristics were evaluated by 
the Pearson correlation coefficient. Differences in the dis-
tribution of baseline parameters (age, BMI, baseline sele-
nium, and plasma Sepp1 concentration) according to GPX1 
rs1050450 and SEPP1 rs3877899 genotypes were evalu-
ated by one-way ANOVA. Repeated measures analysis of 
covariance (ANCOVA, MANCOVA) was carried out to test 
the effects of particular genotype or genotypes interaction 
on the studied biological parameters. With MANCOVA 
analysis, parameters measured at different time points 
were considered as dependent variables, while genotypes 
and covariates were included in the models as independent 
variables. Covariates included age, sex, BMI, and baseline 
selenium. The effect of Se supplementation (time effect/
within subjects effect) as well as the effect of interaction 
between genotype and Se supplementation was assessed 
using MANCOVA test methods (Wilk’s lambda statistics) 
with the unstructured covariance matrix. Post hoc compari-
sons between pairwise time points were performed by con-
trast tests. All the assays were performed at a significance 
level of α = 0.05. In order to take into account the problem 
of multiple comparisons, along with original p values, the 
false discovery rate (FDR), adjusted p values were also cal-
culated and reported in the text, where appropriate. Statisti-
cal analyses were conducted using SAS software, version 
9.2 (SAS Institute, Cary, NC, USA).
Results
Course of the study
All the individuals completed the supplementation trial. 
There was also 100 % responsiveness to the question-
naires introduced at each time point of blood collection, 
and all the subjects reported to take Se yeast tablets regu-
larly (1 tablet/day) for 6 weeks. Nobody declared smok-
ing tobacco and taking Se containing supplements during 
the study. Dietary questionnaires concerned frequency of 
consumption of food products which contain the highest 
Se content in the Polish diet (according to our previous 
study [26]). As shown in supplementary figures (Figure 
S2), the overall consumption frequency of eggs, fish, and 
nuts was similar during 6-week period of supplementation 
as compared to the washout. Additionally, we collected 
data on factors (consumption of drugs, hormones, dietary 
supplements etc.) that could potentially affect results of 
the study (Table S2). Subjective side effects observed 
during supplementation, as reported by two female par-
ticipants included short nausea directly after taking the 
supplement (one female) and vaginal thrush (the other 
female).
Sex and genotype differences at baseline
Significant differences between males and females at base-
line were observed for BMI (24.9 vs. 22.8, respectively, 
p < 0.0001) and GPx1 activity (16.1 vs. 18.2 U/g Hb, 
p = 0.01). Significant positive correlations with age were 
found in females for BMI (ρ = 0.34, p = 0.01), plasma Se 
or Sepp1 concentrations (ρ = 0.51, p = 0.0001; ρ = 0.39, 
p = 0.02, respectively), and TBARS (ρ = 0.43, p = 0.002). 
In males, positive significant correlations with age were 
observed only for TBARS (ρ = 0.54, p = 0.0002).
Numbers of male and female subjects within each geno-
type subgroup were similar (Table 2). There were no signif-
icant differences at baseline in terms of age, BMI, and Se 
status between the subjects with different GPX1 genotype. 
SEPP1 polymorphism was shown to significantly affect 
the baseline plasma Se concentration (in a linear manner), 
whereas no baseline differences were observed in terms of 
age, BMI, and plasma Sepp1 concentration.
Se supplementation effects
Table 3 presents median values and a range of mark-
ers for selenium status (plasma concentrations of Se and 
Sepp1), oxidative stress (the activities of GPx1, GPx3, 
SOD1 and Cp, TAC, TBARS, and ROS generation), and 
DNA damage (at the level of DNA strand breaks and 
DNA oxidation) measured at baseline, during the supple-
mentation trial and after 4 weeks of the washout period. 
Both plasma Se and Sepp1 median concentrations were 
significantly increased after 2 weeks of supplementa-
tion (98.00 µg/L vs. 62.65 µg/L and 7.36 vs. 3.86 ng/mL, 
respectively; p < 0.0001 and p < 0.0001, respectively) and 
after 6 weeks of supplementation (93.84 µg/L and 6.14 ng/
mL, respectively; p < 0.0001 and p < 0.0001 vs. baseline, 
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respectively). After 4 weeks of washout, Se started to 
decrease (74.61 µg/L, p < 0.0001 vs. 6 weeks); however, 
it was still significantly higher as compared to the baseline 
(p < 0.0001), whereas Sepp1 was not statistically different 
as compared to the median value observed after 6 weeks of 
supplementation (6.00 ng/mL, p = 0.270). GPx1 and GPx3 
activities were significantly higher as compared to the 
baseline after 6 weeks of supplementation (24.43 vs. 17.10 
U/gHb and 0.20 vs. 0.18 U/mL, respectively; p < 0.0001 
and p < 0.0001, respectively), and both started to decrease 
slightly after 4 weeks of the washout period, though sta-
tistically significant difference as compared to the sixth 
week’s value was observed only for GPx3 (0.19 U/mL, 
p < 0.0001). Total plasma antioxidant capacity as well as 
lipid peroxidation was significantly increased already after 
2 weeks of supplementation (p = 0.02 and p = 0.0002 vs. 
baseline, respectively) and remained significantly higher 
as compared to the baseline after 6 weeks of supplemen-
tation (p < 0.0001 and p < 0.0001, respectively) and after 
4 weeks of the washout period (p < 0.0001 and p < 0.0001 
vs. baseline, respectively). Plasma Cp activity was signifi-
cantly increased after 6 weeks (p = 0.003 vs. baseline) and 
remained significantly higher as compared to the base-
line after 4 weeks of washout (p = 0.01). SOD1 activity 
remained unaffected during the supplementation trial. The 
ability of whole-blood granulocytes to generate ROS upon 
PMA stimulation, measured only after 2 weeks of supple-
mentation, was significantly decreased as compared to the 
baseline (p < 0.0001). A statistically significant increase 
in DNA damage, assessed at three time points, as com-
pared to the baseline, was observed after 4 weeks of the 
washout period, both at the level of DNA strand breaks 
(p < 0.0001 vs. the baseline) and at the level of DNA oxida-
tion (p < 0.0001 vs. baseline).
Table 4 presents mean values of the normalized rela-
tive gene expression, analyzed at baseline, after 2 weeks 
of supplementation, after 6 weeks of supplementation, and 
after 4 weeks of the washout period. Five out of eight ana-
lyzed genes (GPX1, GPX4, SEP15, SELS, and SELW) were 
affected in a negative manner upon Se supplementation. 
Table 3  Effect of Se supplementation on the studied biological parameters, including markers of selenium status, oxidative stress and DNA 
damage. Data presented regardless of genotype
Statistically significant p values (last column) and values significantly different as compared to baseline are typed in bold. Values indexed with 
different upper case letters (a, b, c, d) are significantly different at p ≤ 0.05 (contrast test for different time points, adjusted for age, sex, BMI, 
and baseline plasma Se)
na parameter was not analyzed at this time point
* Skewed data; for these parameters, p values were calculated for log-transformed data
** Model adjusted for age, sex, BMI, and baseline plasma Se
Marker Median and range, measured at four different time points p value (MANCOVA)**
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Expression of mRNA for these genes was significantly 
decreased as compared to the baseline after 6 weeks of sup-
plementation (p = 0.0002 for GPX1, p = 0.001 for GPX4, 
p < 0.0001 for SEP15, p < 0.001 for SELS, and p < 0.0001 
for SELW) and remained significantly decreased as com-
pared to the baseline after 4 weeks of the washout period 
(p < 0.0001 for GPX1, p = 0.0001 for GPX4, p < 0.0001 for 
SEP15, p < 0.0001 for SELS, and p < 0.001 for SELW). For 
two genes (GPX4, SEP15), a significant decrease as com-
pared to the baseline was observed already after 2 weeks 
of supplementation (p = 0.006 and p = 0.02, respectively). 
SEPP1 expression was the only case in which the expres-
sion was increased upon Se supplementation. However, the 
increase was not statistically significant as compared to the 
baseline, and it was significantly decreased after 4 weeks of 
the washout period (p = 0.001 and p = 0.0002 vs. 2 weeks 
and 6 weeks, respectively). Expression of the two genes, 
TRXR1 and SBP2, remained unaffected.
SNP alone effects and the interaction with Se 
supplementation
The effects of GPX1 rs1050450 and SEPP1 rs3877899 
polymorphisms are presented in Table 5 and Table S3. The 
effects were analyzed regardless of time and with respect 
to time interaction to assess the possible modulatory SNP 
effects upon Se supplementation.
Se status
Plasma Se and Sepp1 concentrations were not associated 
with GPX1 rs1050450 (p = 0.94 and p = 0.17, respec-
tively) or SEPP1 rs3877899 (p = 0.08 and p = 0.13, 
respectively) nor with the combination of those two poly-
morphisms (p = 0.36, p = 0.84, respectively, Table 5). 
No modulatory effects were also observed for any of the 
two SNPs on the dynamic changes in Se status markers in 
response to Se supplementation (as assessed by the tests for 
interaction with time).
Oxidative stress and DNA damage
Statistically significant effects of GPX1 rs1050450 on 
GPx1 activity (p = 0.04, Table 5) and DNA oxidation 
(p = 0.002; Table 5) were observed regardless of time (at 
each time point). According to the contrast tests, GPX1 
LeuLeu homozygotes were shown to differ significantly 
as compared to ProPro homozygotes and ProLeu heterozy-
gotes, having the lowest GPx1 activity (Fig. 1a) and, at the 
same time, the highest level of DNA oxidation (Fig. 3). 
Additional analysis of mean GPx1 activity change after 
6 weeks of Se supplementation with respect to GPX1 
rs1050450 genotype confirmed the significant impact of 
this SNP on enzyme activity response, showing that GPX1 
LeuLeu individuals were characterized by a significantly 
lower increase upon supplementation as compared to 
the individuals possessing ProPro genotype (p = 0.008; 
Fig. 1b).  
After inclusion of time effect (SNP and time interac-
tion), GPX1 rs1050450 was observed to modulate the 
response to Se supplementation at the level of GPx3 activ-
ity (p = 0.05; Table 5; Fig. 2). In the explorative analysis 
of particular time points, GPx3 response was shown to 
be affected by the genotype specifically after 6 weeks of 
supplementation and during washout, with significantly 
higher values as compared to the baseline observed for Pro-
Pro homozygotes (p < 0.0001 and p = 0.002 for 6 weeks 
and washout, respectively) and ProLeu heterozygotes 
p = 0.001 and p = 0.02 for 6 weeks and washout, respec-
tively), whereas GPx3 activity in LeuLeu homozygotes was 
not affected (p = 0.21 and p = 0.66 for 6 weeks and wash-
out, respectively).
Table 4  Selectively 
suppressive effect of selenium 
supplementation at the level 
of mRNA expression (relative 
expression, normalized to 
GAPDH). Data presented 
regardless of genotype
Statistically significant p values and mean values significantly different as compared to baseline expression 
are typed in bold. Values indexed with different upper case letters (a, b, c, d) are significantly different at 
p ≤ 0.05 (contrast test for different time points, adjusted for age, sex, BMI, and baseline plasma Se)
* Model adjusted for age, sex, BMI, and baseline plasma Se
Gene Mean and SD, measured at four different time points p value, 
(MANCOVA)*
Baseline 2 weeks 6 weeks Washout
GPX1 1.425 ± 0.212a 1.411 ± 0.187a 1.355 ± 0.194b 1.292 ± 0.208c p < 0.0001
GPX4 1.355 ± 0.217a 1.294 ± 0.189b 1.284 ± 0.193b 1.251 ± 0.206c p = 0.002
TRXR1 1.742 ± 0.226 1.721 ± 0.197 1.748 ± 0.195 1.736 ± 0.208 p = 0.60
SEPP1 1.555 ± 0.292a,c 1.590 ± 0.316a,b 1.620 ± 0.284a,b 1.467 ± 0.318a,c p = 0.001
SEP15 1.625 ± 0.179a 1.579 ± 0.181b 1.526 ± 0.165c 1.536 ± 0.223c p < 0.001
SELS 2.039 ± 0.274a 1.977 ± 0.245a 1.916 ± 0.217b 1.886 ± 0.309b p < 0.0001
SELW 1.220 ± 0.218a 1.183 ± 0.218a,b 1.115 ± 0.213b 1.125 ± 0.250b p = 0.0003
SBP2 1.470 ± 0.212 1.476 ± 0.183 1.472 ± 0.233 1.493 ± 0.210 p = 0.73
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Statistically significant SNP and time interaction was 
shown for GPX1 rs1050450 also at the level of DNA strand 
breaks (p = 0.05; Table 5; Fig. 4). According to the analy-
sis of particular time points, a significant increase in DNA 
damage, as compared to the baseline, was shown at wash-
out and only for ProPro homozygotes (p < 0.0001).
Significant SEPP1 rs3877899 effect was limited only 
to the response of SOD1 activity upon Se supplementation 
(p = 0.02 for SNP and time interaction, Table 5; Fig. 5). 
According to the analysis of particular time points, a sig-
nificant SOD1 decrease, as compared to the baseline, was 
observed specifically for AlaAla homozygotes during 
washout (p = 0.04).
mRNA expression
GPX1 rs1050450 and SEPP1 rs3877899 SNPs were not 
associated with any changes in the expression of related 
(encoded) genes. GPX1 rs1050450 was shown to modulate 
the expression of unrelated target, SEP15, upon Se supple-
mentation, both alone (p = 0.03) and in combination with 
SEPP1 rs3877899 (p = 0.04; Table S3).
False discovery rate analysis
After FDR correction of p values, significant effects were 
maintained for all the analyzed data regardless of the gen-
otype (Tables 3, 4), whereas most of the effects analyzed 
after genotype stratification were no more statistically sig-
nificant (data not shown). The only genotype modulatory 
effect that remained statistically significant after FDR cor-
rection was the effect of GPX1 rs1050450 polymorphism 
on DNA oxidation, regardless of time (FDR p values: 0.02).
Discussion
Final evidence that GPX1 Leu variant at rs1050450 is 
associated with a lower GPx1 response to Se
This supplementation trial, conducted among 95 non-smok-
ing individuals, prospectively genotyped for two redox 
active selenoproteins, confirmed the previously observed 
effect of GPX1 rs1050450 on GPx1 activity response to 
Se supplementation [24, 35]. Glutathione peroxidase is an 
Table 5  Effects of GPX1 rs1050450 and SEPP1 rs3877899 polymorphisms on the markers of selenium status, oxidative stress and DNA dam-
age, interaction with time
Statistically significant p values are typed in bold and supplied with graphical explanation on the indicated figure. For the interaction with time, 
only statistically significant p values are presented. Statistically nonsignificant effects are shown in the supplementary Figures S3a-q
* Models adjusted for age, sex, BMI, and baseline plasma Se
** Skewed data; for these parameters, p values were calculated for log-transformed data
Parameter p value for genotype effect (ANCOVA)* and for time interaction (MANCOVA)*
GPX1 rs1050450 SEPP1 rs3877899 GPX1 rs1050450 × SEPP1 rs3877899
Se (µg/L) p = 0.94 p = 0.08 p = 0.36
Sepp1** (ng/mL) p = 0.17 p = 0.13 p = 0.84
GPx1 (U/gHb) p = 0.04
(Fig. 1a)
p = 0.33 p = 0.59
GPx3 (U/mL) p = 0.47
Interaction with time:
p = 0.05 (Fig. 2)
p = 0.33 p = 0.48
SOD1 (U/mg Hb) p = 0.91a p = 0.76
Interaction with time:
p = 0.02 (Fig. 3)
p = 0.64
Cp (g/L) p = 0.20 p = 0.70 p = 0.33
TAC** (mmol/L) p = 0.76 p = 0.37 p = 0.97
TBARS** (mmol/mL) p = 0.09 p = 0.15 p = 0.65
RFT (MFI index) p = 0.14 p = 0.95 p = 0.74




p = 0.72 p = 0.47
DNA oxidation (% tail DNA) p < 0.0001
(Fig. 5)
p = 0.62 p = 0.65
2478 Eur J Nutr (2016) 55:2469–2484
1 3
important antioxidant enzyme, which is responsible for 
reducing hydrogen peroxide in the presence of reduced 
glutathione [36]. Although GPx1 is Se-dependent enzyme, 
its activity relies also on other different factors, includ-
ing age, sex, smoking status, and health condition [37–39]. 
To exclude the modifying effect of some of these vari-
ables, the study included only the non-smoking individuals 
who reported themselves to be free from chronic diseases, 
whereas sex and age were included in the analysis as covari-
ates. Functional effects linked to GPX1 rs1050450 polymor-
phism, associated with proline (Pro)-to-leucine (Leu) sub-
stitution at codon 198 (or 200), were originally observed in 
MCF7 cells [35] and supported by some [27, 37, 40], though 
not all [41], human observational studies. Altogether, GPX1 
variant (Leu) allele has been suggested to cause lower 
responsiveness of GPx1 to Se. However, this hypothesis 
has not been entirely confirmed in human supplementation 
trials. Miller et al. [24] combined the results of two separate 
randomized, placebo-controlled double-blind trials (RCT), 
in which subjects (n = 255) with coronary artery disease 
were supplemented with 100 µg of Se (as SeMet) per day 
for 12 weeks. Average increase in GPx1 activity in the 
patients with at least one Leu allele was significantly lower 
as compared to ProPro homozygotes, but the difference 
between the genotypes was most evident in the subjects with 
Fig. 1  a GPX1 rs1050450 effect on GPx1 activity in the individuals 
supplemented with selenium. A significant SNP effect was observed 
regardless of time. Data adjusted for age, sex, BMI, and baseline sele-
nium; b mean GPx1 activity increase after 6 weeks of supplementa-
tion, with respect to GPX1 genotype. Data adjusted for age, sex, 
BMI, and baseline GPx1 activity. p values for the ANCOVA/MAN-
COVA and contrast tests indicated in the figures
Fig. 2  GPX1 rs1050450 effect on GPx3 activity in the individuals 
supplemented with selenium. A significant SNP effect was observed 
in the interaction with time. Data adjusted for age, sex, BMI, and 
baseline selenium. p values for the MANCOVA indicated in the fig-
ure. According to the particular time points analysis, a significant 
difference in GPx3 activity as compared to baseline was shown after 
6 weeks of supplementation and during the washout period for Pro-
Pro (p < 0.0001 and p = 0.002, respectively) and ProLeu (p = 0.001 
and p = 0.02, respectively)
Fig. 3  GPX1 rs1050450 effect on DNA oxidation (expressed as % of 
DNA in comet tail) in the individuals supplemented with selenium. A 
significant SNP effect was observed regardless of time. Data adjusted 
for age, sex, BMI, and baseline selenium. p values for the MAN-
COVA and contrast test indicated in the figure 
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the lowest baseline plasma Se concentration (83–99 µg/L). 
The second, smaller study was conducted among 37 obese 
women considered as Se-deficient (with the mean baseline 
plasma Se concentrations in different genotype groups rang-
ing from 54 to 62 µg/L), who were supplemented with Bra-
zil nuts for 8 weeks (providing 290 µg of Se/day) [25]. The 
authors have observed different magnitude of GPx1 activ-
ity increase depending on GPX1 genotype; however, the 
difference was not statistically significant, possibly due to 
the low sample size (only five LeuLeu homozygotes). Our 
study, which was conducted among individuals with a rela-
tively low baseline Se status (mean plasma Se 62.6 µg/L), 
provides final evidence, indicating that GPX1 Leu allele at 
rs1050450 is associated with a lower GPx1 response to Se 
supplementation, specifically in the individuals with low Se 
dietary intake. This observation excludes the utility of GPx1 
activity as a useful biomarker of Se status in supplemen-
tation trials, not only in the high Se status but also among 
the low Se status population, as previously suggested by us 
[27]. Furthermore, we also observed that GPX1 rs1050450 
polymorphism modulated the response of other peroxi-
dase, GPx3, showing no enzyme responsiveness in the case 
of Leu homozygotes, after 6 weeks of supplementation. 
Because this SNP effect was not target related, the exact 
relationship remains unclear, though possibly resulting from 
strong redox-related interactions between both (erythrocyte 
and plasma) glutathione peroxidases.
Unclear association between GPX1 polymorphism, Se 
supplementation, and DNA damage during washout
On the basis of their study, Miller et al. [24] have con-
cluded that individuals possessing Leu allele(s) have a 
higher demand for Se compared to ProPro homozygotes, 
suggesting that they may especially benefit from Se supple-
mentation in terms of a decreased risk of cancer or other 
diseases. This hypothesis, though being very promising 
in terms of personalized nutrition, has never been verified 
by human long-term supplementation trials, and further-
more, human gene association studies indicate for a rather 
unclear relationship between GPX1 polymorphism and 
cancer (detailed review in [42]). Following the hypothesis 
considering antioxidant activity of selenoproteins as one 
of the anticancer mechanisms exerted by Se, it is surpris-
ing that only few authors have investigated the relationship 
between GPx1 activity and any disease risk in a prospec-
tive manner. To our knowledge, only two such studies have 
been conducted, indicating significant inverse correlations 
in breast cancer [43] or coronary artery disease [44]. Thus, 
it should be noted that even though the possible relation-
ship between GPX1 polymorphism and the risk of cancer 
may exist, there is no epidemiological evidence that GPx1 
upregulation caused specifically by Se supplementation 
may decrease such a risk, and that such supplementation 
should be especially beneficial in GPX1 LeuLeu individu-
als with a low Se status. Some insights into a possible ben-
eficial effect of Se supplementation specifically in GPX1 
LeuLeu individuals may be obtained by the analysis of the 
relationship between GPX1 rs1050450 polymorphism and 
cancer risk-related biomarkers, such as DNA damage, in 
the Se supplemented individuals. Such an analysis, so far, 
Fig. 4  GPX1 rs1050450 effect on DNA strand breaks (expressed as 
% of DNA in comet tail) in the individuals supplemeted with sele-
nium. A significant SNP effect was observed in the interaction with 
time. Data adjusted for age, sex, BMI, and baseline selenium. p 
values for the MANCOVA indicated in the figure. According to the 
particular time point analysis, a significant difference in DNA strand 
breaks as compared to baseline was shown during washout for ProPro 
homozygotes, p < 0.0001
Fig. 5  SEPP1 rs3877899 effect on SOD1 activity in the individuals 
supplemented with selenium. A significant SNP effect was observed 
in the interaction with time. Data adjusted for age, sex, BMI, and 
baseline selenium. p values for the MANCOVA indicated in the fig-
ure. According to the particular time point analysis, a significant 
difference in GPx3 activity as compared to baseline was shown for 
AlaAla homozygotes during washout (p = 0.04)
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has been conducted only in two human supplementation 
trials. Caple et al. [22] analyzed the effect of GPX1 poly-
morphism on DNA damage (as assessed by comet assay) 
in blood lymphocytes of 48 subjects receiving 100 µg of Se 
(in the form of antioxidant supplement containing also vita-
mins A, E, and C) for 6 weeks. No modifying effects of this 
SNP have been observed, either at the level of endogenous 
DNA damage, or at the level of peroxide-induced DNA 
damage (as expressed by percent of DNA in comet tail). In 
contrast, a significant effect of GPX1 polymorphism at the 
level of DNA damage has been observed in Brazil obese 
women in the already mentioned study, indicating that after 
8 weeks of Brazil nuts consumption, ProPro homozygotes 
(n = 18) had lower DNA damage (measured by comet 
length), as compared to the baseline. Surprisingly, LeuLeu 
homozygotes (n = 5) apparently did not benefit from the 
supplementation, having significantly higher DNA dam-
age after 8 weeks as compared to the wild-type homozy-
gotes [25]. In our study, we observed that Se supplemen-
tation had no effect on DNA damage (regardless of the 
baseline values, as assessed in the MANCOVA model) 
but, intriguingly, the levels of both DNA oxidation and 
DNA strand breaks were significantly increased as com-
pared to baseline, after 4 weeks following discontinuation 
of supplementation. Notably, this specific time point was 
during (not after) washout, as both plasma Se and Sepp1 
markers (being significantly increased by intervention) still 
remained high. LeuLeu homozygotes had a significantly 
higher level of DNA oxidation as compared to ProPro and 
ProLeu subjects, which could be linked to the lower GPx1 
activity as compared to ProPro or ProLeu; however, these 
genotype differences in DNA oxidation were independent 
of time, clearly indicating that GPx1 increase caused by Se 
supplementation did not improve DNA repair specifically 
in LeuLeu homozygotes (nor did it in two other genotypes). 
Furthermore, considering DNA oxidation, the LeuLeu indi-
viduals seemed also to be the most negatively affected after 
supplementation discontinuation. In contrast, specifically 
ProPro homozygotes seemed to be the only genotype which 
was negatively affected by Se supplementation discontinu-
ation at the level of DNA strand breaks, notwithstanding 
with the observation from the Brazil study (showing ProPro 
homozygotes to have decreased DNA damage after con-
sumption of high Se content nuts) or with the observational 
study in New Zealanders in whom the lower DNA damage 
as a function of increasing serum Se level has been shown 
in ProPro homozygotes, but not in the ProLeu or LeuLeu 
subjects [23, 25]. Nevertheless, we failed to indicate that 
GPX1 LeuLeu homozygotes may especially benefit from 
Se supplementation in terms of decreased DNA dam-
age, which is consistent with the observed DNA damage 
effect in the LeuLeu subjects from the Brazil study [25]. 
Instead, we observed that GPX1 polymorphism modulated 
a specific negative “withdrawal effect” linked to Se supple-
mentation discontinuation.
The overall observation of increased DNA damage dur-
ing washout (shown regardless genotype) was somewhat 
unexpected and points to unrecognized properties of Se that 
may be assigned to specific chemical forms of Se present 
in Se yeast. The composition of Se yeast largely depends 
on the supplier [45], and considering that different chemi-
cal forms of Se have different cytotoxic and biochemical 
effects [46], it may not be excluded that some forms of 
Se exert deleterious effects on genomic stability. Blessing 
et al. indicated for example that reducible Se compounds 
such as phenylseleninic acid, phenylselenyl chloride, sele-
nocystine, ebselen, and 2-nitrophenylselenocyanate are 
able to affect zinc finger proteins involved in DNA repair 
[47].
Se supplementation was associated with overlapped 
prooxidant and antioxidant effects, accompanied 
by selective suppression of selenoprotein mRNA 
expression
Considering daily dietary intake in Polish population 
(20–59 µg), the average daily intake of the element in this 
study during supplementation should have not exceeded 
the upper tolerable limits of 300 or 400 µg/day, set by 
the European Scientific Committee on Food or US Food 
and Nutrition Board [4, 48]; thus, no toxic effects were 
expected. Furthermore, post-supplementation plasma Se 
concentrations in the study individuals (55–149 µg/L) were 
close to or lower than those reported in plasma or serum 
in other short-term Se supplementation trials, such as SEL-
GEN (109 µg/L, plasma), Danish study (126–154 µg/L, 
serum), New Zealand study (142.1 µg/L, plasma), or Bra-
zil study (127–148 µg/L, plasma) [21, 24, 25, 49], and 
notably, it was even lower than presupplementation values 
observed in the long-term supplementation trials such as 
NPC (114 µg/L, plasma) or SELECT (135 µg/L, serum) 
[13, 50]. However, we observed that Se supplementation 
was associated with a significant increase in lipid peroxi-
dation, which occurred already after 2 weeks of interven-
tion and which did not diminish after 4 weeks of washout. 
This prooxidant effect was accompanied by the overall 
increased ability to challenge oxidative stress (as indicated 
by higher activities of GPx1, GPx3, Cp, and higher plasma 
antioxidant capacity), suggesting some overlapped antioxi-
dant and prooxidant processes, possibly resulting from the 
overlapped activity of different Se compounds present in 
Se yeast [45]. At the same time, mRNA expression in white 
blood cells (WBC) for five selenoprotein-encoding genes 
(GPX1, GPX4, SEP15, SELS, and SELW) was significantly 
decreased, suggesting that such a negative transcriptional 
feedback could have been induced by excess of Se. In other 
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words, additional intake of 200 µg of Se may be considered 
too high in the study group. Selenoprotein mRNA expres-
sion in WBC has been proposed as a potential marker of 
Se status [51, 52]. However, studies conducted in humans 
point to no correlation between selenoprotein gene expres-
sion in blood and plasma/serum Se in the subjects supposed 
to be already Se repleted or possessing relatively high base-
line Se status [49, 52, 53]. In contrast, Pagmantidis et al. 
[54] have observed a subtle increase in mRNA expression 
for SPS1, SEP15, and SELK in the individuals with base-
line plasma Se = 93.9 µg/L (n = 39,) who were supple-
mented with selenate for 6 weeks. The only study which 
is partially consistent with our results is a 12-week Se sup-
plementation trial joined with trivalent influenza vaccina-
tion at week 10th. In the trial, 119 non-smoking men (age 
50–64 years) with the mean plasma Se concentration of 
95.5 µg/L were supplemented with Se in a form of Se yeast 
(50,100, or 200 µg/day) or Se-enriched onions (50 µg), 
and a significant decrease in mRNA expression has been 
observed after 10 weeks of supplementation (before vac-
cination) for SELW in the highest Se dose group (200 µg/
day Se yeast) as compared to the placebo. For the two other 
analyzed selenoproteins (SELS and SELR), no changes in 
mRNA expression have been reported during Se supple-
mentation (before vaccination) [55]. Notably, both SELW 
and SELS were decreased upon Se supplementation in our 
study. Altogether, the effect of Se intervention on mRNA 
selenoprotein expression in humans seems to be selective 
and possibly depends on the chemical form of Se (as sup-
ported by in vitro study [56]) as well as on the baseline Se 
status. Our study, which was conducted among the subjects 
with the lowest baseline Se status, as compared to other tri-
als discussed indicated that a high dose intervention in the 
subjects with a relatively low dietary intake induced selec-
tive selenoprotein mRNA decrease. One cannot exclude 
that this negative transcriptional feedback resulted from a 
specific redox dysregulation linked to a too high difference 
in the redox state between presupplementation and (post)
supplementation period, which consequently prevented the 
adaptation process to occur. This hypothesis seems in line 
with the new concept of reductive stress, which may be 
induced by upregulated GPx1 activity [42].
Minor effect of SEPP1 rs3877899 polymorphism
The second SNP of interest in this study, SEPP1 
rs3877899, associated with the alanine (Ala) into threonine 
(Thr) change in the polypeptide chain at codon 234, was 
shown to affect expression of different Sepp1 isoforms, 
showing that variant (Thr) allele is associated with lower 
proportions of 60-kDa isoform, and that plasma Sepp1 
concentration may depend on the interaction between this 
SNP and sex [21, 57]. In our study, we failed to find any 
effect of SEPP1 polymorphism on Sepp1, either at the 
level of protein or mRNA. However, we observed that the 
SNP affected plasma Se concentration at baseline, with 
the lower levels in the subjects possessing Thr allele(s), 
and this effect was also observed during a supplementa-
tion trial at the level approaching statistical significance 
(p = 0.08). Meplan et al. have observed that SEPP1 poly-
morphism modified the levels of plasma Se in a response 
to supplementation in BMI-dependent manner, suggest-
ing that SEPP1 may affect response to Se specifically in 
the individuals with higher BMI (higher than 30). In this 
study, as assessed by MANCOVA model, we failed to find 
such an interaction, possibly due to the small number of 
individuals with BMI higher than 30 (no BMI effects on 
plasma Se response were observed, either alone or in com-
bination with SEPP1 genotype, data not shown). Meplan 
et al. have observed several other, not target related, effects 
of SEPP1 rs3877899 polymorphism, linked to the affected 
expression or activity of specific selenoproteins in blood 
compartments (TRxR1, GPx1, or GPx4). The authors have 
concluded that different expression of Sepp1 associated 
with SEPP1 rs3877899 polymorphism may affect expres-
sion and activities of other selenoproteins by influencing Se 
supply to different tissues. In our study, such effects were 
minor and they concerned combined and time-dependent 
effect of GPX1 and SEPP1 polymorphisms on SEP15 
expression, which may reflect the complexity of interac-
tions within human selenoproteome, pointing to its depend-
ence on Se supply and Se-dependent redox regulation. The 
other SEPP1 effect, observed in the interaction with time 
and linked to the activity of Se-independent antioxidant 
enzyme, superoxide dismutase 1, was rather not consistent 
and difficult to explain, though it may confirm some meta-
bolic link between Sepp1 expression and redox pathway 
related to glutathione peroxidases as a product of SOD1 
(hydrogen peroxide) is a substrate for GPx1 and GPx3.
Study limitations
The major limitation of the study concerns multiple test-
ing, which could have generated false associations. Indeed, 
after the false discovery rate analysis was conducted, most 
of the observed effects were no more statistically signifi-
cant. However, the most significant effects (relationship 
between GPX1 polymorphism and GPx1 activity as well 
as DNA oxidation) were in line with the previous hypoth-
eses and observations. Other limitation of the study is asso-
ciated with the fact that the study was not randomized as 
the subjects were selected according to the genotype, and 
the genotype distribution in the study group was not repre-
sentative of the whole population. However, since we espe-
cially aimed at analyzing the effects of minor alleles, such 
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selection seems to be justified. Finally, the reported results 
were not further confirmed by an independent replication 
analysis and need to be verified.
Conclusions
Lack of beneficial effects of Se supplementation in the indi-
viduals with a relatively low Se status, as indicated in this 
study at the level of DNA damage, does not provide molecu-
lar basis for the hypothesis on anticancer activity of the ele-
ment in the populations with its low dietary intake. Overall, 
our study confirmed the functional effect of GPX1 rs1050450 
polymorphism linked to the lower GPx1 activity response to 
Se supplementation; however, it did not support the hypothesis 
that individuals possessing GPX1 variant allele(s) may espe-
cially benefit from the increased Se intake. Findings linked to 
the suppressed mRNA expression of selected selenoproteins 
and prooxidant effects observed during supplementation war-
rant further investigation, whereas observation of the increased 
DNA damage during washout may give further insights into 
the unclear relationship between DNA damage and Se [47, 
58]. Intriguingly, the possible modifying effect of GPX1 poly-
morphism on DNA damage during washout may shift the cur-
rent interest of genetic profiling of selenoproteins from ques-
tion “who may benefit from Se supplementation,” into “who 
may be less harmed by such a kind of intervention.”
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